2020 American Transplant Congress
Multimodal Strategy for Hepatocellular Carcinoma in the Elderly: To Transplant or Not to Transplant
1Columbia University Irving Medical Center, New York, NY, 2Weill Cornell Medicine, New York, NY
*Purpose: Liver transplantation LT for HCC is curative but entails increased risk and is limited by organ scarcity. Alternative approaches such as locoregional therapy (LRT)…2020 American Transplant Congress
Left Lobe Living Donor Liver Transplantation Using Rapid Procedure in a Cirrhotic Patient with Hepatocellular Carcinoma with a GRWR of 0.35
*Purpose: Here, we describe a new approach using Rapid Procedure, a 2 stage hepatectomy technique, with living donor liver transplantation (LDLT) in the cirrhotic setting…2020 American Transplant Congress
Factors Associated with Hepatocellular Carcinoma Understaging for Liver Transplantation, and Variation in Understaging by Transplant Center
1Hospital of the University of Pennsylvania, Philadelphia, PA, 2University of Miami, Miami, FL
*Purpose: Hepatocellular carcinoma (HCC) may be cured by liver transplantation (LT) in selected patients, though recurrence rates remain high. Patients who are reported as within…2020 American Transplant Congress
Beyond Milan- Not Paying the Price
Columbia University, New york, NY
*Purpose: Early stage hepatocellular carcinoma (HCC) patients meeting the Milan Criteria have access to Orthotopic Liver Transplantation (OLT) as a curative treatment. However, a substantial…2020 American Transplant Congress
A Population-Based Analysis of Hepatocellular Carcinoma in Children: Identifying Optimal Surgical Treatment
*Purpose: Hepatocellular carcinoma (HCC) constitutes 0.5% of childhood malignancies and exhibits poor prognosis. Complete tumor extirpation either by partial liver resection (LR) or liver transplantation…2020 American Transplant Congress
Effects of Mandatory 6-Month Waiting Time Policy on Post-Transplant Outcomes and Explant Pathology in Liver Transplant Patients with Hepatocellular Carcinoma
Henry Ford Hospital, Detroit, MI
*Purpose: In the United States, current allocation policy mandates a 6-month waiting period before exception scores are granted to liver transplant (LT) candidates with hepatocellular…2020 American Transplant Congress
The Prognostic Impacts of Recipient Gender in Deceased Donor Liver Transplantation for Hepatocellular Carcinoma
The Cleveland Clinic, Cleveland, OH
*Purpose: Hepatocellular carcinoma (HCC) is significantly male predominant cancer. Sex hormonal signal is considered to play some roles, although exact underlying mechanisms are not fully…2020 American Transplant Congress
Everolimus-Treatment Inhibits the Transition of the Immature Subsets of Liver Natural Killer Cells to Mature State and Enhances Anti-Tumor Activity
Gastreenterological and Transplant Surgery, Hiroshima University, Hiroshima, Japan
*Purpose: The immunosuppressive regimen currently used after organ transplantation efficiently reduces the adaptive immune components. During suppressed adaptive immunity, the innate immune cells may play…2020 American Transplant Congress
National Trends in Locoregional Therapy among Liver Transplant (LT) Candidates with Hepatocellular Carcinoma (HCC) in the United States
1Stanford University, Redwood City, CA, 2University of California, San Francisco, San Francisco, CA
*Purpose: Advances in locoregional therapy (LRT) have expanded treatment options for patients with HCC. As recent policy changes in the United States (US) have lengthened…2020 American Transplant Congress
Post-Transplant Recurrence Following Yttrium-90 Treatment in Liver Transplant Recipients with Hepatocellular Carcinoma
Transplant and Hepatobiliary Surgery, Henry Ford Hospital, Detroit, MI
*Purpose: Yttrium-90 microspheres radioembolization (Y90) has shown to be effective as a bridging therapy for patients with advanced hepatocellular carcinoma (HCC) while on waiting list…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 18
- Next Page »